Tanimilast is a novel and selective inhaled inhibitor of phosphodiesterase-4 in advanced clinical development for chronic obstructive pulmonary disease (COPD). Tanimilast is known to exert prominent anti-inflammatory activity when tested in preclinical experimental models as well as in human clinical studies. Recently, we have demonstrated that it also finely tunes, rather than suppressing, the cytokine network secreted by activated dendritic cells (DCs). This study was designed to characterize the effects of tanimilast on T-cell polarizing properties of DCs and to investigate additional functional and phenotypical features induced by tanimilast.
The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation
Nguyen, Hoang Oanh;Salvi, Valentina;Tiberio, Laura;Gaudenzi, Carolina;Passari, Mauro;Schioppa, Tiziana;Sozio, Francesca;Del Prete, Annalisa;Bosisio, Daniela
2022-01-01
Abstract
Tanimilast is a novel and selective inhaled inhibitor of phosphodiesterase-4 in advanced clinical development for chronic obstructive pulmonary disease (COPD). Tanimilast is known to exert prominent anti-inflammatory activity when tested in preclinical experimental models as well as in human clinical studies. Recently, we have demonstrated that it also finely tunes, rather than suppressing, the cytokine network secreted by activated dendritic cells (DCs). This study was designed to characterize the effects of tanimilast on T-cell polarizing properties of DCs and to investigate additional functional and phenotypical features induced by tanimilast.| File | Dimensione | Formato | |
|---|---|---|---|
|
Nguyen et al J Transl Med 2022.pdf
accesso aperto
Descrizione: Nguyen et al J Transl Med 2022.pdf
Tipologia:
Full Text
Licenza:
PUBBLICO - Creative Commons 4.0
Dimensione
2.16 MB
Formato
Adobe PDF
|
2.16 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
